CLINICAL TRIALS PROFILE FOR CYTOXAN (LYOPHILIZED)

All Clinical Trials for CYTOXAN (LYOPHILIZED)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00691015 ↗	Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant	Completed	National Cancer Institute (NCI)	Phase 2	2008-05-01	RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus, and antithymocyte globulin before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of giving sirolimus together with tacrolimus and antithymocyte globulin and to see how well it works in preventing graft-versus-host disease in patients with hematologic cancer who are undergoing donor stem cell transplant.
NCT00691015 ↗	Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant	Completed	Barbara Ann Karmanos Cancer Institute	Phase 2	2008-05-01	RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus, and antithymocyte globulin before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of giving sirolimus together with tacrolimus and antithymocyte globulin and to see how well it works in preventing graft-versus-host disease in patients with hematologic cancer who are undergoing donor stem cell transplant.
NCT06078696 ↗	Siplizumab for Sickle Cell Disease Transplant	Recruiting	ITB-Med LLC	Phase 1/Phase 2	2023-09-28	The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure. The main goals of this study are : - To determine if acute GVHD occurs and how severe the acute GVHD is in subjects receiving the study drug - To determine if graft failure occurs in subjects receiving the study drugs In this study, participants will receive 5 infusions of the study drug, siplizumab, while getting a stem cell transplant for SCD. Before siplizumab infusion, participants will be given medications to reduce the risks of allergic reaction to the drug.
NCT06078696 ↗	Siplizumab for Sickle Cell Disease Transplant	Recruiting	Markus Mapara	Phase 1/Phase 2	2023-09-28	The purpose of this study is to find out whether siplizumab is safe and effective for patients with SCD undergoing an allogeneic transplant and to prevent development of Graft versus Host Disease (GVHD) and graft failure. The main goals of this study are : - To determine if acute GVHD occurs and how severe the acute GVHD is in subjects receiving the study drug - To determine if graft failure occurs in subjects receiving the study drugs In this study, participants will receive 5 infusions of the study drug, siplizumab, while getting a stem cell transplant for SCD. Before siplizumab infusion, participants will be given medications to reduce the risks of allergic reaction to the drug.
NCT06186401 ↗	Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells	Recruiting	California Institute for Regenerative Medicine (CIRM)	Phase 1	2024-03-04	This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Lymphodepleting chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make the CAR T cells more effective.
NCT06186401 ↗	Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells	Recruiting	National Cancer Institute (NCI)	Phase 1	2024-03-04	This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Lymphodepleting chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make the CAR T cells more effective.

Clinical Trial Conditions for CYTOXAN (LYOPHILIZED)

Condition Name

Condition Name for CYTOXAN (LYOPHILIZED)
Intervention	Trials
EGFR Gene Mutation	1
Glioblastoma	1
Leukemia	1
Lymphoma	1

Condition MeSH

Condition MeSH for CYTOXAN (LYOPHILIZED)
Intervention	Trials
Myelodysplastic-Myeloproliferative Diseases	1
Syndrome	1
Myelodysplastic Syndromes	1
Preleukemia	1

Clinical Trial Locations for CYTOXAN (LYOPHILIZED)

Trials by Country

Trials by Country for CYTOXAN (LYOPHILIZED)
Location	Trials
United States	3

Trials by US State

Trials by US State for CYTOXAN (LYOPHILIZED)
Location	Trials
California	1
New York	1
Michigan	1

Clinical Trial Progress for CYTOXAN (LYOPHILIZED)

Clinical Trial Phase

Clinical Trial Phase for CYTOXAN (LYOPHILIZED)
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	1
Phase 1	1

Clinical Trial Status

Clinical Trial Status for CYTOXAN (LYOPHILIZED)
Clinical Trial Phase	Trials
Recruiting	2
Completed	1

Clinical Trial Sponsors for CYTOXAN (LYOPHILIZED)

Sponsor Name

Sponsor Name for CYTOXAN (LYOPHILIZED)
Sponsor	Trials
National Cancer Institute (NCI)	2
Markus Mapara	1
California Institute for Regenerative Medicine (CIRM)	1

Sponsor Type

Sponsor Type for CYTOXAN (LYOPHILIZED)
Sponsor	Trials
Other	4
NIH	2
Industry	1

CYTOXAN (LYOPHILIZED): Clinical Trials Update and Market Projection

Last updated: April 23, 2026

What is CYTOXAN (lyophilized) in the regulatory and product landscape?

CYTOXAN (lyophilized) is an injectable, lyophilized formulation of cyclophosphamide (small-molecule alkylating agent). Cyclophosphamide is a cornerstone oncology agent used in multiple chemotherapy and conditioning regimens, with clinical development dominated by label expansion, combination studies, and post-approval trials rather than new chemical entity pathways.

Core implication for a patent/clinical-trials view: CYTOXAN as a branded drug is a long-established product; clinical activity typically appears as (1) comparative or combination studies using cyclophosphamide, (2) dosing, formulation, and administration studies, and (3) trials in specific disease settings and conditioning paradigms.

What does the clinical-trials pipeline look like for cyclophosphamide broadly?

A current view across registered trial databases shows cyclophosphamide is active in:

• Oncology combination regimens (solid tumors and lymphoid malignancies)
• Hematologic malignancies and transplantation conditioning
• Autoimmune indications (historically and in selected ongoing studies)

However, for a branded lyophilized product like CYTOXAN, the most decision-relevant “pipeline” is often indirect: trials usually test cyclophosphamide in a regimen rather than prove the lyophilized brand’s incremental value, unless a formulation-specific question is studied (reconstitution, stability, administration route, or comparative PK/PD).

Net effect: the “clinical trials update” for CYTOXAN (lyophilized) should be treated as cyclophosphamide regimen evidence rather than a brand-specific late-stage development track.

What recent clinical-trials signals matter for commercialization?

Decision-grade signals for a branded, off-patent cytotoxic typically cluster into three buckets:

1) Dose and schedule refinements

Clinical studies frequently evaluate:

• Cyclophosphamide dosing schedules within combination regimens
• Toxicity management and supportive care alignment (growth factors, antiemetics)
• Administration timing in transplantation or conditioning

Commercial meaning: fewer “new trials” translate into brand differentiation unless label or guideline adoption explicitly requires a particular formulation or administration method.

2) Guideline and regimen uptake

Cyclophosphamide remains embedded in:

• Lymphoma regimens
• Breast cancer combinations
• Conditioning regimens used in autologous and allogeneic transplantation frameworks

Commercial meaning: brand demand tends to track the volume of regimen use and institutional formulary decisions, not brand-specific efficacy.

3) Formulation and procurement behavior

For lyophilized injectables, procurement and supply chain stability often drive:

• Conversion between lyophilized and liquid presentations where available
• Tender preferences for consistent supply and reconstitution usability

Commercial meaning: brand share can be constrained by availability of generics and alternative presentations even when clinical use stays constant.

What is the likely patent and exclusivity posture for CYTOXAN (lyophilized)?

CYTOXAN is an established branded product of cyclophosphamide. In practice, cyclophosphamide itself is not commercially protected as a new chemical entity in current markets, and brand exclusivity typically does not extend into a meaningful late-life moat for a long-established cytotoxic.

For business planning, treat CYTOXAN (lyophilized) as:

• A legacy branded injectable competing with generic cyclophosphamide and alternative formulations
• A product where differentiation is typically operational (supply, labeling, handling) rather than clinical superiority

How should market size be analyzed for CYTOXAN (lyophilized)?

A defensible market view requires separating: 1) Therapeutic demand for cyclophosphamide (driven by regimen volumes) 2) Share of injectable lyophilized cyclophosphamide within that demand (driven by product preference, tendering, and substitution)

A branded lyophilized product’s addressable market is therefore a slice of the much larger cyclophosphamide drug class.

Market drivers by use case

• Oncology chemotherapy regimens: steady oncology demand and regimen-based use
• Hematology and transplantation conditioning: transplant volume and practice patterns
• Supportive and salvage use: cytotoxic backbone behavior

Market constraints

• Generic substitution: cyclophosphamide generics typically exert strong price competition
• Formulation substitution: where liquid or alternate presentations exist, procurement can shift

What is the projection for CYTOXAN (lyophilized) volumes and revenues?

Without brand-specific historical shipment data in the prompt, the only rigorous projection structure is a scenario framework anchored to cyclophosphamide class behavior: volume tends to be stable-to-slow growth; revenue tends to be flat to declining in real terms under generic price pressure.

Projection logic (revenue vs. volume)

• Volume (units): tends to follow chemotherapy and transplant procedure volumes, with modest growth from:
  • Incidence trends and treatment intensification
  • Regimen expansion in certain oncology subgroups
• Revenue (net sales): compresses due to:
  • Generics discounting
  • Tender-based pricing
  • Ongoing competitive replenishment cycles

Practical projection direction for a branded lyophilized product

For CYTOXAN (lyophilized), the most likely commercial path is:

• Units: stable to modest growth (because cyclophosphamide remains in standard-of-care frameworks)
• Revenue: flat to decline versus earlier years due to generic substitution and price compression

What would a “market share” trajectory look like?

Given the market structure for older cytotoxics:

• Brand share often trends toward stabilization after early substitution cycles
• Future share depends on:
  • Institutional formularies
  • Contract pricing dynamics
  • Supply continuity

For CYTOXAN (lyophilized), absent formulation exclusivity, the share outlook is typically:

• Moderate share erosion risk in competitive tender environments
• Stabilization potential where brand-specific handling, availability, or distribution reach matters to procurement teams

Where do clinical trials most likely influence CYTOXAN (lyophilized) specifically?

Clinical trial influence becomes direct when a trial:

• Uses cyclophosphamide in a way that becomes a guideline-referenced standard
• Includes a formulation-specific element (route and presentation) that affects adoption
• Generates subgroup evidence that expands use in a manner consistent with injectable cyclophosphamide schedules

In most modern registries, formulation-specific evidence for a legacy branded lyophilized product is limited; clinical trial impact usually flows through cyclophosphamide regimen uptake rather than “CYTOXAN (lyophilized) adoption.”

Actionable investment and R&D implications

For R&D / business development teams

• Treat CYTOXAN (lyophilized) as a commercial and supply-chain asset, not a late-stage clinical innovation platform.
• If pursuing adjacent development, focus on:
  • Regimen optimization evidence with cyclophosphamide
  • Patient selection biomarkers that drive cyclophosphamide inclusion rates
  • Formulation, stability, or administration usability improvements that reduce procurement friction

For investors

• CYTOXAN’s value proposition in a portfolio is primarily:
  • Cashflow predictability from entrenched oncology use
  • Defensive positioning through manufacturing reliability
• Upside is constrained by generics; downside is typically price-based rather than efficacy-based.

Key Takeaways

• CYTOXAN (lyophilized) is cyclophosphamide; clinical activity in the current era is mostly regimen- and indication-level, not brand-formulation specific.
• The commercial outlook for a branded lyophilized legacy cytotoxic generally shows stable-to-modest volume growth with flat-to-declining revenue under generic price competition.
• Market share is primarily driven by procurement and tender pricing, with brand differentiation usually operational (supply, handling) rather than clinical.

---

FAQs

1) Does the current clinical pipeline create brand-specific differentiation for CYTOXAN (lyophilized)?

Usually not. Most evidence supports cyclophosphamide regimens, with formulation-specific proof limited for a legacy lyophilized brand.

2) What indications most affect cyclophosphamide demand?

Oncology chemotherapy regimens, hematologic malignancies, and transplantation conditioning practices are the main demand drivers.

3) How do generics impact CYTOXAN (lyophilized) pricing?

Generics typically compress net pricing through tender-based discounting, constraining branded revenue growth even if units stay stable.

4) What drives procurement decisions for a lyophilized injectable?

Supply continuity, reconstitution usability, contract pricing, and formulary status often dominate.

5) What is the most realistic revenue trajectory for a legacy branded cytotoxic?

Flat to declining revenue over time under continued generic substitution, with stabilization possible where contracts favor supply reliability.

---

References

[1] U.S. Food and Drug Administration. Cyclophosphamide drug label and prescribing information resources. FDA Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] National Library of Medicine. ClinicalTrials.gov search results for cyclophosphamide. https://clinicaltrials.gov/